16,571 Shares in Quest Diagnostics Incorporated $DGX Purchased by Foster & Motley Inc.

Posted by Geri Gentry on Aug 19th, 2026

Foster & Motley Inc. purchased a new position in shares of Quest Diagnostics Incorporated (NYSE:DGX – Free Report) in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm purchased 16,571 shares of the medical research company’s stock, valued at approximately $3,512,000.

A number of other hedge funds and other institutional investors have also modified their holdings of DGX. Vanguard Group Inc. grew its holdings in Quest Diagnostics by 1.0% during the fourth quarter. Vanguard Group Inc. now owns 14,392,082 shares of the medical research company’s stock worth $2,497,458,000 after purchasing an additional 140,450 shares during the period. BlackRock Inc. bought a new stake in shares of Quest Diagnostics in the second quarter valued at about $1,965,923,000. State Street Corp grew its position in shares of Quest Diagnostics by 3.0% during the 4th quarter. State Street Corp now owns 5,382,547 shares of the medical research company’s stock worth $934,033,000 after purchasing an additional 158,617 shares in the last quarter. Boston Partners increased its stake in Quest Diagnostics by 32.8% during the 3rd quarter. Boston Partners now owns 4,036,881 shares of the medical research company’s stock worth $767,978,000 after acquiring an additional 997,033 shares during the period. Finally, Morgan Stanley grew its stake in Quest Diagnostics by 17.8% during the fourth quarter. Morgan Stanley now owns 2,693,568 shares of the medical research company’s stock worth $467,415,000 after buying an additional 406,658 shares in the last quarter. Institutional investors and hedge funds own 88.06% of the company’s stock.

Quest Diagnostics Stock Performance

NYSE DGX opened at $236.71 on Wednesday. The company has a fifty day moving average price of $217.00 and a 200-day moving average price of $204.06. The firm has a market cap of $26.13 billion, a price-to-earnings ratio of 25.13, a PEG ratio of 2.16 and a beta of 0.56. The company has a debt-to-equity ratio of 0.72, a current ratio of 1.59 and a quick ratio of 1.46. Quest Diagnostics Incorporated has a 1 year low of $171.18 and a 1 year high of $240.13.

Quest Diagnostics (NYSE:DGX – Get Free Report) last posted its quarterly earnings data on Thursday, July 23rd. The medical research company reported $3.12 earnings per share for the quarter, topping the consensus estimate of $2.82 by $0.30. The business had revenue of $3.04 billion for the quarter, compared to analysts’ expectations of $2.97 billion. Quest Diagnostics had a return on equity of 16.01% and a net margin of 9.18%.The business’s revenue was up 10.2% on a year-over-year basis. During the same quarter in the previous year, the firm earned $2.62 earnings per share. Quest Diagnostics has set its FY 2026 guidance at 11.050-11.250 EPS. As a group, equities research analysts predict that Quest Diagnostics Incorporated will post 11.15 EPS for the current fiscal year.

Quest Diagnostics Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, October 21st. Investors of record on Tuesday, October 6th will be paid a dividend of $0.86 per share. This represents a $3.44 dividend on an annualized basis and a dividend yield of 1.5%. The ex-dividend date is Tuesday, October 6th. Quest Diagnostics’s dividend payout ratio is presently 36.52%.

Insider Buying and Selling

In related news, CEO J. E. Davis sold 10,000 shares of the stock in a transaction dated Monday, June 1st. The stock was sold at an average price of $194.14, for a total transaction of $1,941,400.00. Following the sale, the chief executive officer owned 132,423 shares of the company’s stock, valued at approximately $25,708,601.22. This represents a 7.02% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Mark E. Delaney sold 1,600 shares of the firm’s stock in a transaction dated Tuesday, July 28th. The stock was sold at an average price of $235.18, for a total value of $376,288.00. Following the completion of the transaction, the senior vice president owned 10,335 shares of the company’s stock, valued at approximately $2,430,585.30. This represents a 13.41% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders sold 19,747 shares of company stock valued at $3,947,088. Company insiders own 0.88% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms have issued reports on DGX. Barclays lifted their target price on Quest Diagnostics from $230.00 to $250.00 and gave the company an “overweight” rating in a research report on Thursday, July 23rd. Evercore set a $225.00 price target on Quest Diagnostics in a research note on Tuesday, April 21st. Weiss Ratings raised shares of Quest Diagnostics from a “buy (b+)” rating to a “buy (a-)” rating in a research report on Wednesday, August 12th. Jefferies Financial Group reissued a “buy” rating and issued a $245.00 price objective on shares of Quest Diagnostics in a research report on Thursday, July 23rd. Finally, JPMorgan Chase & Co. upped their target price on Quest Diagnostics from $220.00 to $250.00 and gave the company a “neutral” rating in a research report on Tuesday, July 28th. One equities research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and seven have issued a Hold rating to the stock. According to data from MarketBeat.com, Quest Diagnostics currently has a consensus rating of “Moderate Buy” and an average price target of $235.31.

Read Our Latest Stock Report on DGX

About Quest Diagnostics

(Free Report)

Quest Diagnostics (NYSE: DGX) is a leading provider of diagnostic information services that supports clinical decision-making for patients, physicians and healthcare organizations. The company operates a network of clinical laboratories and patient service centers that perform a broad range of laboratory tests and diagnostic assays used in routine care, disease diagnosis, monitoring and screening.

Its services span core clinical laboratory testing, anatomic pathology, molecular and genomic diagnostics, infectious disease testing and toxicology.